Lithotripsy

Associated Medical Professionals of NY Adds Robert Creaven as Chief Operating Officer

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Nursing, Health, Hospitals, Practice Management, Other Health, General Health, Physician, Villanova University, MSO, Negotiation, Long Island University, Bachelor, Staten Island University Hospital, Information system, Patient, Farmingdale State College, Hospital, Lithotripsy, Health administration, Robotics, Operation, Pathology, Practice management, Radiation, A.M.P, NMS, Business development, Associate, Organization, Medicine, Science, Central New York

is pleased to announce that Robert Creaven has been named Chief Operating Officer.

Key Points: 
  • is pleased to announce that Robert Creaven has been named Chief Operating Officer.
  • Associated Medical Professionals of NY is a leading multi-specialty practice spanning 19 locations in Central New York, including ten offices and nine hospitals.
  • Angelo R. DeRosalia, M.D., Chairman and CEO of Associated Medical Professionals of NY, and President and Board Member of U.S. Urology Partners , stated, We are excited to have Robert Creaven join the team at A.M.P.
  • Robert Creaven, Chief Operating Officer of Associated Medical Professionals of NY , stated, I am honored to join Associated Medical Professionals of NY and impressed with the highly skilled physician leaders and their care teams, who are focused on delivering the best care to patients first and foremost.

EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration

Retrieved on: 
Monday, September 26, 2022
Risk, COVID-19, TMS, Laser, Q&A, Company, Lithotripsy, EDAP, Focal, U.S. Securities and Exchange Commission, ESWL, Langham Hotel, London, Annual report, Nasdaq, Security (finance), Google Images, HIFU, Prostate cancer, Medical imaging

LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.

Key Points: 
  • LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
  • Please join the company in-person or virtually as it hosts an event featuring:
    A Focal One Robotic focal HIFU introduction from EDAP's U.S. CEO
    A live Q&A session will follow the formal presentations.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

The Worldwide Kidney Stone Retrieval Devices Industry is Expected to Reach $3.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022
Medical Devices, Health, Adoption, Time-invariant system, Incidence, COVID-19, Prevalence, Anesthesia, Growth, Lithotripsy, Kidney, USD, Patient, Investment, ESWL, Diagnosis, Research, Mergers and acquisitions, Boston Scientific, BD, Recurrence, CAGR, Pharmaceutical industry

Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.

Key Points: 
  • Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.
  • Considerably smaller ureter scopes, quartz fibers, and lithotripter probes have made the extraction of kidney stones from previously unreachable locations far safer than traditional surgical options.
  • For instance, the Dretler stone cone is one innovation that inhibits stone migration during the treatment.
  • The demand for kidney stone retrieval devices was uneven, with installation delays and a decline in manufacturing during the pandemic.

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Medical Devices, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Cardiology, FDA, Artery, Hank, University of Michigan, Population, POWER, Lithotripsy, Interventional cardiology, Industry, Generalized arterial calcification of infancy, Patient, CEO, State university system, BS, MBA, Technology, IVL, Royal Perth Hospital, AVS, Pennsylvania Hospital, Board of directors, Hillrom, PULSE, Dominican Republic, Pulse, Calcium, Board, Moyamoya disease, Elective surgery, Boston Scientific, Virginia Tech, Leg, University, Pharmaceutical industry, Medical imaging

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.

ADVANCED MEDTECH ACQUIRES WIKKON, STRENGTHENING ITS MARKET LEADING POSITION IN UROLOGY MEDICAL DEVICES

Retrieved on: 
Tuesday, September 13, 2022
Engineering, Erectile dysfunction, Name, Acquisition, Life, Medtech, Dornier, Industry, Kidney, Patient, Entrepreneurship, Ministry of Education (Malaysia), Physician, ESWL, Technology, Solution, Integration, Arthralgia, ESWT, Research, Dornier Flugzeugwerke, Urology, Lithotripsy, Fine chemical, Medical device, Medical imaging, Pharmaceutical industry, Video game console, Group, Temasek

Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.

Key Points: 
  • Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.
  • Abel Ang, Group Chief Executive of Advanced MedTech, said: We are now uniquely placed to aggressively grow in Chinas sizeable market, which is best served by domestically produced devices.
  • Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and contract manufacturing services.
  • Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world.

First-on-Podium Data from 21 Vascular Interventional Clinical Trials to Be Presented at The VEINS and VIVA 2022

Retrieved on: 
Thursday, September 1, 2022
Treatment, Wynn Las Vegas, Research, Virtual, Awareness, Health and Quality of Life Outcomes, Subgroup analysis, Vascular disease, Physician, Diagnosis, Education, Multimedia, Human, STRIDE, Disrupt, Multicenter trial, Observational study, Blood vessel, VIVA, Lithotripsy, Pharmaceutical industry, Medicine, Medical imaging

VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.

Key Points: 
  • VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.
  • The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders.
  • VIVA and The VEINS bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.
  • Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

$1.87 Billion Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecasts, 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022
Medical Devices, Health, FDA, Woman, Fluoroscopy, Man, Risk, Medical device regulation, National Kidney Foundation, ESWL, Population, Technology, Growth, USD, CT, Incidence, Public employment services in the European Union, Prevalence, Urology, Coronary artery disease, Dornier, COVID-19, Kidney, Acquisition, Lithotripsy, Shock, Ageing, Chronic kidney disease, Awareness, Competitive landscape, CAGR, Plaque, Boston Scientific, US, Patient, Certification, Efficiency, MDR, Rock, Pharmaceutical industry, Medical imaging

The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Global Lithotripsy Devices Market was valued at USD 1.44 billion in 2021, growing at a CAGR of 4.35% during the forecast period from 2022 to 2027, to reach USD 1.87 billion by 2027.
  • Such technological advancement in the field of Lithotripsy Devices is likely to boost the Global Lithotripsy Devices Market during the forecast period.
  • Which are the regions and countries where companies should have concentrated on opportunities for Lithotripsy Devices market growth in the coming future?

Insights on the Energy-Based Therapeutics Global Market to 2027 - by Technology Type, Clinical Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Health, Biotechnology, Therapy, Cryotherapy, COVID-19, Skin, Degenerative disease, Tissue, Red, ENT, Arrhythmia, Adoption, Surgeon, Nature, Glaucoma, Greg Camp, 3D ultrasound, Cataract, Pigment, Lithotripsy, Acne, Energy, Gynaecology, Pharmaceutical industry, Medical imaging, Dentistry, Medical device, Potash, Healthcare, Distribution (marketing)

These therapeutics are divided on the basis of clinical applications into general, ophthalmic and aesthetic surgeries.

Key Points: 
  • These therapeutics are divided on the basis of clinical applications into general, ophthalmic and aesthetic surgeries.
  • Key Questions Answered in This Report:
    How has the global energy-based therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global energy-based therapeutics industry and who are the key players?
  • What is the degree of competition in the global energy-based therapeutics industry?

US Surgical Procedures Market Analysis Report 2022-2027: Focus on Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022
Surgery, Health, Health, CAGR, Population, Patient, Rhinoplasty, Colonoscopy, Ageing, Elective surgery, Conditional sentence, ENT, Cancer, Growth, ASC, Diabetic retinopathy, Eye, Glaucoma, Urology, Cataract, Lithotripsy, Awareness, Prevalence, Dentistry, Hospital

The "US Surgical Procedures Market by Type (Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures), Channel (Physician Offices, Hospitals, (Inpatient, Outpatient), ASC) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Surgical Procedures Market by Type (Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures), Channel (Physician Offices, Hospitals, (Inpatient, Outpatient), ASC) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Advances in surgical, anesthetic, and intensive care techniques have led a larger proportion of expanding elderly population to undergo surgical procedures, which will drive the growth of the US surgical procedures market.
  • Based on type, the US surgical procedures market is segmented into gastrointestinal surgical procedures, cardiovascular surgical procedures, dental surgical procedures, cosmetic surgical procedures, urologic surgical procedures, ophthalmic surgical procedures, orthopedic surgical procedures, ENT surgical procedures, obstetric/gynecologic surgical procedures, and other surgical procedures.
  • In 2021, the dental surgical procedures segment accounted for the largest share of this market.

EDAP Reports First Quarter 2022 Results

Retrieved on: 
Tuesday, May 17, 2022
ET, Weill Cornell Medical Center, EUR, Nasdaq, UC Davis Medical Center, Lithotripsy, Webcast, Patient, Investment, Urology, HIFU, Review, USD, EDAP, Association, Total, Academic health science centre, Prostate cancer, University, Technology, Weill Cornell Medicine, American Urological Association, Distribution, Harvard Medical School, Pharmaceutical industry, Video game, Film

Total revenue in the HIFU business for the first quarter 2022 was EUR 3.8 million (USD 4.3 million), as compared to EUR 1.8 million (USD 2.2 million) for the first quarter of 2021.

Key Points: 
  • Total revenue in the HIFU business for the first quarter 2022 was EUR 3.8 million (USD 4.3 million), as compared to EUR 1.8 million (USD 2.2 million) for the first quarter of 2021.
  • Total revenue in the LITHO business for the first quarter 2022 was EUR 2.2 million (USD 2.5 million), as compared to EUR 2.9 million (USD 3.5 million) for the first quarter of 2021.
  • Total revenue in the Distribution business for the first quarter 2022 was EUR 7.0 million (USD 7.8 million), as compared to EUR 5.6 million (USD 6.7 million) for the first quarter of 2021.
  • Operating loss for the first quarter of 2022 was EUR 0.1 million (USD 0.1 million), compared to an operating profit of EUR 0.2 million (USD 0.3 million) in the first quarter of 2021.